

REMARKS


In view of the failure of the USPTO to consider the Declaration Under 37 C.F.R. §1.131, Applicants have withdrawn their appeal and file the present Request for Continued Examination. The Declaration swears behind the references disclosed in the Information Disclosure Statement of March 5, 2004 and the patent to Buyuktimkin et al. In view of the fact that the final rejection relied upon Buyuktimkin et al. as a reference, the examiner should now reconsider whether rejection is proper.

More importantly, the examiner is requested to reconsider applicants arguments set forth in the responses filed December 15, 2003 and on May 28, 2003. Applicants submit that even if Buyuktimkin et al. could be considered prior art, the previously presented claims define a patentable invention over the references cited.

New claims 55-58 have been added to expedite prosecution. Claims 55 and 56 fully distinguish over prior art that failed to recognize the use of misoprostol and/or misoprostol acid as a primary active for use in facilitating female sexual satisfaction. Claim 57 recites an active agent consisting essentially of a mixture of a misoprostol compound and alprostadil. Claim 58 recites a misoprostol compound and a second agent other than histamine or histamine receptor agonist.

Applicants respectfully request that the examiner reconsider this application in view of all of the art. Applicants submit that the present application is in condition for allowance and early notice to that effect is respectfully solicited.

Respectfully submitted,



Robert M. Asher
Reg. No. 30,445
Bromberg & Sunstein LLP
125 Summer Street, 11th Floor
Boston, MA 02110-1618
(617) 443-9292
Attorney for Applicants